More tools:Markets·Screener·Research·Chat

Incannex Healthcare Limited American Depositary Shares (IXHL) Financial Statements

Incannex Healthcare Limited American Depositary Shares
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG01J0814Z1
XNAS · usd
3.32▼ 0.05 (-1.55%)
As of 2026-09-09
Valuation
Market Cap
Enterprise Value—
Trailing P/E—
Price / Sales—
EV / Revenue—
EV / EBITDA—
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin—
Net Debt—
Trading Information
Previous Close3.37
Day's Range3.26 – 3.44
52-Week Range0.15 – 6.91
Volume47.2K
Avg Volume85.0K
Share Statistics
Shares Outstanding
Employees12
ExchangeXNAS
Listed2022-02-25
Share count as of May 15, 2026
Loading Income Statement…
Key questions about Incannex Healthcare Limited American Depositary Shares (IXHL)
What is Incannex Healthcare Limited American Depositary Shares's Market Cap?
Incannex Healthcare Limited American Depositary Shares's Market Cap is $39.7M, based on as-reported figures from SEC (XBRL) filings.
What is Incannex Healthcare Limited American Depositary Shares's Revenue (TTM)?
Incannex Healthcare Limited American Depositary Shares's Revenue (TTM) is $0.00, based on as-reported figures from SEC (XBRL) filings.
What is Incannex Healthcare Limited American Depositary Shares's Net Income (TTM)?
Incannex Healthcare Limited American Depositary Shares's Net Income (TTM) is -$48.4M, based on as-reported figures from SEC (XBRL) filings.
What is Incannex Healthcare Limited American Depositary Shares's EBITDA?
Incannex Healthcare Limited American Depositary Shares's EBITDA is -$25.1M, based on as-reported figures from SEC (XBRL) filings.
What is Incannex Healthcare Limited American Depositary Shares's Diluted EPS (TTM)?
Incannex Healthcare Limited American Depositary Shares's Diluted EPS (TTM) is -4.05, based on as-reported figures from SEC (XBRL) filings.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemMar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022
Revenue from customers———
Operating expenses:
Research and development
General and administrative
Total operating expenses
% of revenue————
Loss from operations
% of revenue————
Other income, net:
R&D tax incentive
Foreign exchange gains/(losses)
Interest expense———
Interest income
Change in fair value of convertible rights———
Change in fair value of warrant liabilities——
Warrant issuance costs——
Loss on extinguishment———
ELOC commitment fee———
Share of earnings (loss) of joint venture—
Total other income, net
Loss before income tax expense
Net loss
% of revenue————
Net loss per share: Basic (in Dollars per share)—
Net loss per share: Diluted (in Dollars per share)—